As endocrine disorders are on the rise, it’s very important that primary care providers take a role in patient management. CGM has the opportunity to improve the lives of patients with endocrine disorders. Orienting PCPs with CGM devices via guided explanations from faculty and hands-on time with available devices will increase their knowledge of CGM as a tool, their confidence in discussing the CGM data with their patients, and competence in integrating CGM tools into their clinical practice.
This educational initiative is intended for primary care clinicians who care for patients with diabetes.
This activity is supported by independent educational grants from Abbott Diabetes Care, Dexcom, Lilly, and Medtronic.
Upon completion of the activity, participants should be able to:
- Review traditional approaches to monitoring glucose
- Discuss continuous glucose monitoring (CGM) and the role it plays in managing patients with diabetes
- Identify patients for whom CGM use is appropriate
- Interpret CGM results
- Involve patients in interpretation of CGM results
- Use CGM results to provide continued support for patients with diabetes in the primary care setting
The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Endocrinology designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
An important note about ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 ABIM MOC Part II points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Step 1: To receive MOC points, you MUST pass the posttest and complete the evaluation. Complete all questions under the "ABIM Questions" section, located at the bottom of the course evaluation form. This includes 1) attesting that our partner may submit your credits to ABIM, 2) attesting that you are ABIM board certified, 3) providing your ABIM #, and 4) providing your date of birth (MM/DD).
Step 2: For ABIM MOC points, your information will be shared with the ABIM through AACE's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
Accredited Provider Disclosure
The planners, reviewers, editors, staff, CME committee, or other members at the American Association of Clinical Endocrinologists (AACE) who control content have no relevant financial relationships to disclose.
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation (TFF) who control content have no relevant financial relationships to disclose.
Conflict of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinologists (AACE) and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE and TFF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE and TFF are committed to providing learners with high-quality CME.
Disclosure of Unlabeled Use
AACE and TFF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
The American Association of Clinical Endocrinologists and The France Foundation present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinologists, The France Foundation, and the commercial supporter(s) assume no liability for the information herein.
Archana Sadhu, MD
Assistant Professor of Clinical Medicine, Academic Institute
Weill Cornell Medical College
Dr. Sadhu serves on the speakers bureau for Sanofi Aventis.
Jay H Shubrook DO, FAAFP, FACOFP
Professor, Primary Care Department
Director of Clinical Research
Director of Diabetes Services
Touro University California
Dr. Shubrook serves on an advisory board for Bayer, Novo Nordisk, and Sanofi.
Jane Jeffrie Seley DNP, MPH, MSN, GNP, RN, BC-ADM, CDCES, CDTC, FADCES, FAAN
Program Manager & Diabetes Nurse Practitioner
Diabetes Care & Education Specialist
Weill Cornell Medicine
Ms. Seley has no relevant financial relationships to disclose.